Close

Acadia Pharma's (ACAD) NUPLAZID Approved by FDA For Hallucinations and Delusions Associated with Parkinson's

May 2, 2016 7:00 AM EDT Send to a Friend
Late Friday, ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) announced that the U.S. Food and Drug Administration (FDA) has approved NUPLAZID (pimavanserin) ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login